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Antibiotic-functionalized Gold Nanoparticles for the Detection of 
Active -lactamases  
Lisa M. Miller,*a Matthew D. Simmons,b Callum D. Silver,c Thomas F. Krauss,c Gavin H. Thomas,d 
Steven D. Johnsonb and Anne-Kathrin Duhme-Klaira
Antimicrobial resistance (AMR) continues to threaten the effective treatment and prevention of bacterial infections. The 
spread of resistant infections is accelerated by the lack of fast and cost-effective tests for the detection of AMR at the point-
of-care. We aimed to address this challenge by developing a diagnostic tool to detect one of the major forms of AMR, the 
-lactamase enzymes. Antibiotic-functionalized gold nanoparticles (AuNPs) have been successfully developed for the 
detection of -lactamases in challenging biological media, namely undiluted urine. Furthermore, these tools are compatible 
with samples containing a urine sample preservative (boric acid) or hematuria (blood). The functionalized AuNPs interact 
with the active -lactamases, resulting in the hydrolysis of the surface-bound antibiotics, which then inhibits binding of the 
AuNPs to a capture protein (a penicillin-binding protein) to indicate the presence of active -lactamases. We successfully 
integrated the antibiotic-functionalized AuNPs into a new lateral flow assay (LFA), which can be used to detect active 
-lactamases down to the detection limit of 11 nM. While we demonstrate the use of antibiotic-functionalized AuNPs in an 
LFA format to provide a novel method of detecting active -lactamases, these functionalized AuNPs are amenable to a range 
of alternative diagnostic technologies and could lead to vital point-of-care diagnostics for the early detection of multi-drug 
resistant infections.
Introduction
Antimicrobial resistance (AMR) is a well-recognized problem in 
the healthcare system.1 Attempts at combatting the continued 
spread of resistance and the emergence of new forms of 
resistance are fundamentally limited by our ability to detect the 
susceptibility of bacteria to antibiotics rapidly and at the point-
of-care.2 A rapid test for the detection of resistance to a 
commonly prescribed class of antibiotics would provide 
clinicians with valuable information needed to inform 
treatment decisions.3 
For example, bacteria are able to produce -lactamases, 
enzymes that confer resistance to the -lactam antibiotics (such 
as penicillin), which are one of the most commonly-prescribed 
classes of antibiotics.4,5 The extended-spectrum -lactamases 
(ESBLs) pose a severe threat to human health, as these enzymes 
confer resistance to the more advanced antibiotics in this class, 
such as the third generation cephalosporins, thus limiting the 
effective treatments available for such infections.6 
Furthermore, ESBL-producing organisms present with co-
resistance to other classes of antibiotics, thus increasing the 
challenge of treating these infections.7
Currently, there is an unmet need for fast and cost-effective 
tests that provide point-of-care detection of -lactamase 
activity and that can be used directly from a patient’s sample. 
The gold standard test involves culturing bacteria present in a 
patient’s sample and then assessing resistance profiles using 
disk susceptibility tests, a process which can take up to 72 
hours.3 Several rapid tests for these enzymes are available 
commercially but the few that have been developed to work on 
unprocessed clinical samples (namely ESBL NDP Test, β LACTA™, 
and Rapid ESBL Screen kit 98022)8-10 require trained laboratory 
technicians and specialist equipment. The exception is the NG-
Test CTX-M (Bio Trading)11 which is a simple-to-use lateral flow 
assay (LFA) that uses antibodies to recognize a specific family of 
-lactamases present in bacterial isolates, but this test does not 
confirm the activity of the enzymes. 
Previously, we reported the development of a surface-bound, 
clinically-relevant -lactam drug that allowed for the detection 
of -lactamases in undiluted urine.12 This work demonstrated 
that -lactamases are able to recognize and react with the 
surface-bound drug molecules, thereby hydrolyzing the 
-lactam. Hence, it was established that the surface-bound drug 
can be used to probe for/detect -lactamase activity. Here, we 
develop these surface-bound antibiotics for application in 
biosensors, focusing on antibiotic-functionalized gold 
nanoparticles in an LFA format, that allows for the direct 
detection of -lactamase activity. The LFA has been optimized 
for use in undiluted urine in order to improve management of 
urinary tract infections (UTIs), which has an estimated global 
prevalence of 150 million cases a year.13 UTIs are the second 
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most common reason for the prescription of antibiotics14 and 
yet prescribing often takes place without prior testing to 
confirm the treatment efficacy. Therefore, a point-of-care UTI 
test that could identify drug-resistant infections would allow 
the right antibiotic to be chosen and prevent the misuse and 
overuse of antibiotics thus improving patient outcomes and 
helping to prevent the acceleration of antibiotic resistance.15, 16
In this work we describe the preparation of LFAs according to 
the design detailed in Fig. 1 (a). Gold nanoparticles (AuNPs) 
labelled with a -lactam antibiotic (Fig. 1 (b)), act as probes by 
binding selectively to penicillin-binding proteins (PBPs) located 





Fig. 1: LFA using -lactam antibiotic-functionalized AuNPs for 
the detection of -lactamases: (a) design of LFA test strip; (b) 
-lactam antibiotic-functionalized AuNPs: (i) intact -lactam 
and (ii) hydrolyzed -lactam; (c) test readouts of LFA. The final 
LFA also included a control line used to confirm a valid run of 
the assay, as discussed in section 3.3.
intact (non-hydrolyzed) -lactams (Fig. 1 (b) (i)), resulting in 
accumulation of the antibiotic-functionalized AuNPs at the PBP 
test line (red line = negative result , Fig. 1 (c)). When exposed to 
a sample containing active -lactamases, the hydrolyzed 
antibiotic-functionalized nanoparticles (Fig. 1 (b) (ii)) no longer 
bind to the PBPs, preventing capture of nanoparticles at the test 
line (positive test, Fig. 1 (c)). This LFA was used to detect a series 
of five recombinant -lactamases in phosphate buffer saline 
(PBS) and in a complex biological media, namely undiluted urine 
collected from healthy volunteers who were not taking 
antibiotics. Further investigations were carried out to assess the 
compatibility of the antibiotic-functionalized AuNPs with 




The AuNPs were synthesized according to the Turkevich 
method, using sodium citrate to reduce HAuCl4.
17 The average 
size of the AuNPs was characterized by transmission electron 
microscopy (TEM), Fig. 2. The OD were determined using UV/Vis 
spectrophotometry (Shimadzu UV-1800). The synthesized 
AuNPs were typically 20 nm in diameter with an extinction 
coefficient of 9.21 x 108 M-1 cm-1.
Synthesis of Cephalexin-NHS
Cephalexin with an N-hydroxy succinimidyl (NHS) ester tether 
(Fig. 3) ((6R,7R)-7-[(2R)-2-{5-[(2,5-dioxopyrrolidin-1-yl)oxy]-5-
oxopentanamido}-2-phenylacetamido]-3-methyl-8-oxo-5-thia-
1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid) was prepared as 
described previously.18 
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Fig. 3: Chemical structure of cephalexin-NHS
Functionalization of AuNPs
BSA-AuNPs were prepared as follows: To 1 mL of citrate-
stabilized AuNPs (optical density (OD) 1, measured by 
absorption at the max) was added 150 L borate buffer (stock 
concentration 15 mM, pH 9) followed by 150 L of bovine serum 
albumin (BSA) (3% w/v stock in deionized water). The mixture 
was then shaken at room temperature for 10 min using an 
orbital shaker. Thereafter the sample was centrifuged (17,000 x 
g, 30 min) and the supernatant discarded. The BSA-AuNPs were 
then washed, first by resuspension in 500 L of wash buffer (2 
mM borate buffer, pH 9, 5% sucrose, 2% glycerol, 0.5% BSA, and 
0.01% Tween) then by resuspension in PBS. Finally, the BSA-
AuNPs were resuspended in 1 mL of PBS and the OD measured 
by absorption at the max.
Cephalexin-AuNPs were prepared as follows: To a solution of 
BSA-AuNPs, the required cephalexin-NHS analogue was added 
(1 mg/100 L in DMSO) to give a final cephalexin-NHS:AuNP 
ratio of 130,000:1. The mixture was shaken at room 
temperature for 1 h using an orbital shaker, then stored at 4 °C 
overnight, after which the sample was centrifuged (17,000 x g, 
30 min) and the supernatant discarded. The AuNPs were then 
washed with PBS and the final pellet of cephalexin-AuNPs was 
re-suspended in PBS at the required concentration. The 
cephalexin-AuNPs were stored at 4 °C until use, batches were 
used within 48 hours of preparation. Polarization modulation-
infrared reflection-adsorption spectroscopy (PM-IRRAS) was 
used to characterize the surface chemistry used in the 
preparation of cephalexin-AuNPs (Supporting Information, Fig. 
S2).
Streptavidin-AuNPs were prepared as follows: To 1 mL of 
citrate-stabilized AuNPs (OD 1) was added 150 L borate buffer 
(stock concentration 15 mM, pH 9) followed by 150 L of 
streptavidin in PBS (50 mg/mL). The mixture was then shaken at 
room temperature for 10 min using an orbital shaker. 
Thereafter the sample was centrifuged (17,000 x g, 30 min) and 
the supernatant discarded. The streptavidin-AuNPs were then 
washed by resuspension in 500 L of wash buffer (2 mM borate 
buffer, pH 9, 5% sucrose, 2% glycerol, 0.5% BSA, and 0.01% 
Tween). The streptavidin-AuNPs were finally washed again with 
PBS and resuspended in 1 mL of PBS. The OD was measured by 
absorption at the max.
Penicillin-binding Protein 3
PBP3 (recombinant, Escherichia coli) was prepared as described 
previously.12 Briefly, a truncated version of the ftsI gene that 
encoded residues 44 to 588, comprising the known soluble 
domain of FtsI, was amplified from E. coli BW25113 cells using 
whole-cell PCR. The resulting DNA fragment was inserted into 
the vector pBADnLIC2005,19 introducing an N-terminal deca-
histidine tag when expressed. The PBP3 was purified using a 
HisTrap HF column (GE Healthcare) using a refolding protocol (2 
M guanidine HCl, 50 mM KPi (pH 7.8), 200 mM NaCl, 20% 
glycerol, and 20 mM imidazole) to remove any bound ligands 
and then eluted using the elution buffer (50 mM KPi (pH 7.8), 
200 mM NaCl, 20% glycerol, and 500 mM imidazole). The 
protein was then buffer-exchanged to potassium phosphate 
buffer (KPi) (50 mM, 200 mM NaCl, pH 7.8), using a HisTrap 
Desalting (GE Healthcare) column. Stock solutions were diluted 
to the required concentration using PBS. For spotting of PBP3 
onto the nitrocellulose membrane, the NaCl concentration of 
the PBS was increased to 320 mM.
-lactamases
Initial enzyme activity testing was carried out using a blend of 
recombinant -lactamase proteins, expressed in E. coli, 
purchased from Sigma-Aldrich (L7920) and used without further 
purification. The lyophilized powder was dissolved in 50 mM KPi 
(pH 7) and aliquoted into 1 mL aliquots, each containing 40–70 
IU -lactamase I and 6–10 IU -lactamase II. The enzyme stock 
solutions were stored at -80 °C. Experiments to test -lactam 
hydrolysis by -lactamases used x5 dilution of the stock enzyme 
solution. Quartz crystal microbalance with dissipation (QCM-D) 
experiments employed drug-functionalized surfaces that were 
pre-incubated in a stock solution of the -lactamase blend for 
16 h at 37 °C.
-lactamase concentration studies were carried out using 
purified recombinant proteins. CTX-M-1 and AmpC were 
purchased from Abcam plc., Cambridge. TEM-1, CTX-M-15, and 
NDM-1 were expressed in E. coli and purified by His-trap.18 All 
-lactamase solutions were prepared at the desired 
concentration in the required test media (PBS or urine).
QCM-D Experiments
QCM-D sensor functionalization: QCM-D sensors were cleaned 
by UV–ozone treatment (10 min), followed by sonication in a 2% 
Hellmanex III solution (Hellma Analytics, Müllheim, Germany) 
(10 min) and then sonication in Milli-Q water (2 × 10 min), 
followed by UV–ozone treatment (30 min). Cleaned samples 
were functionalized according to the type of surface required. 
BSA-cephalexin surface: Cleaned gold sensors were loaded into 
the QCM-D instrument and functionalized in flow using the 
following solutions: (i) BSA (2 mg in 6 mL PBS) and (ii) 
cephalexin-NHS (3 mg in 6 mL PBS).
PBP3 immobilization by His-trap: Cleaned silicon dioxide 
sensors were functionalized with 3-
mercaptopropyltriethoxysilane (MPTES) by immersion in a 4% 
v/v MPTES/isopropyl alcohol (IPA) solution for 24 h to form a 
thiol-terminated self-assembled monolayer. Sensors were then 
rinsed in IPA and dried with N2 gas. An IDA-maleimide analogue 
(see Supporting Information - compound 4, 
2‐[N‐(carboxymethyl)‐6‐(2,5‐dioxo‐2,5‐dihydro‐1H‐pyrrol‐1‐yl)
hexanamido]acetic acid) was used as the Ni2+ chelating agent. 
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Sensors were functionalized with this analogue by immersion in 
a 0.05% w/v solution of compound 4 in PBS for 24 h. 
Functionalized sensors were finally rinsed in Milli-Q water and 
dried with N2 gas, before being loaded into the QCM-D flow 
modules.
QCM-D running conditions: Once each sensor was installed into 
the flow modules of the Q-Sense E4 system, each chamber was 
filled with Milli-Q water at a flow rate of 100 L/min controlled 
by a four-channel peristaltic pump. To achieve a stable baseline, 
the initial running solution (Milli-Q water or PBS, see QCM-D 
results of specific experiments) was left to flow through the 
modules at 50 L/min until the drift in resonant frequency was 
<±1 Hz over 10 min. For all experiments, the temperature of the 
modules was maintained at 20 °C (standard deviation 5 x 10–
3 °C) and the flow rate was kept constant at 50 L/min. A wash 
solution (see QCM-D results for solutions used) was allowed to 
flow over the sensor surface between sample injections until a 
stable level was achieved, corresponding to a drift in frequency 
<±1 Hz over 10 min. QCM-D spectra showing both the frequency 
and dissipation shifts for the seventh overtone of each 
experiment are provided in the Supporting Information. Surface 
concentrations of proteins were calculated using the Sauerbrey 
equation. We note,  the Sauerbrey model assumes a thin, rigid, 
and uniform layer, and is therefore used here to only provide an 
estimate of surface concentration.
LFA Materials and Construction
Each LFA strip contained four overlapping pads placed on a 
backing card: sample pad (CFSP203000), conjugate pad 
(GFCP103000), membrane (HF090MC100), and absorption pad 
(CFSP203000). Each component overlapped by 2 mm and was 
adhered to a backing card. Once constructed, PBP3 (in PBS with 
320 mM NaCl) was pipetted onto the membrane to form the 
test spot (750 nM, 2 L per strip). The LFA strips were then 
allowed to dry at room temperature before blocking the 
membrane by flowing through a solution of BSA in PBS (50 
g/mL). The LFAs were again dried, then cut into 6 mm wide 
strips and stored in an air tight container at 4 °C.
For LFAs with a control spot, biotinylated-BSA was pipetted to 
the control region of the membrane (100 g/mL in PBS, 0.5 L 
per strip) 3 mm above the PBP3 test region.
LFA Running Protocol
Prior to testing, LFAs were allowed to return to room 
temperature and acclimatize to the ambient conditions for 30 
min. Unless stated otherwise, samples were assayed as follows: 
10 L cephalexin-AuNPs (1 nM) was added to 10 L of the test 
sample and mixed by pipette. The mixture was then incubated 
at 37 C for 1 h before adding to the LFA strip. Running buffer 
(PBS, pH 7.4, 1 mM ETDA, 1% v/v Triton™ X-100) was then 
added until the membrane was clear in the non-binding areas. 
The LFA results were then recorded and documented by 
photograph. Test strips were run in duplicate, alongside strips 
run with control samples of cephalexin-AuNPs incubated in the 
test media to assess media effects.
Urine Samples
An “average” human urine sample was used, as described 
previously.12 Collection and handling of urine samples was 
performed following procedures pre-approved by the 
University of York’s Department of Biology Ethics Committee 
and to comply with the UK Concordat to Support Research 
Integrity (2019). Informed consent was collected from all 
sample donors. Urine samples were collected anonymously 
from 13 healthy adults that had not shown symptoms of 
infection or had taken antibiotics within 1 month prior to the 
sample collection. Participants were recruited from within the 
University of York. Samples were filter-sterilized using 0.22 m 
syringe filters to remove any cells and then pooled to form an 
“average” human urine, which was aliquoted and stored in a 
−80 °C freezer. The pH of the resulting urine was measured to 
be pH 6.7. Control experiments did not detect any β-lactamases 
within the urine stock.
Results and Discussion
Antibiotic-functionalized AuNPs
AuNPs (synthesized via the Turkevich method,17 and 
characterized by UV-Vis spectrophotometry and TEM, details 
provided in section 2.1. and the Supporting Information) were 
first functionalized with BSA to produce a protein coating that 
was found to preserve hydrophilicity (optimization of AuNP 
surface chemistry is provided in the Supporting Information). 
Furthermore, this layer was designed to act as a barrier to 
reduce biofouling (non-specific adsorption of proteins) of the 
AuNPs when used for detection in biological samples, such as 
urine. The BSA-AuNPs were then further functionalized with 
probe antibiotics using an NHS ester analogue of cephalexin 
(chemical structure shown in Fig. 3), which reacts with the lysine 
residues of BSA to attach the antibiotic via amide bonds, Fig. 1 
(b) (i). Optimization of the concentration of cephalexin-NHS was 
required as at high concentrations the antibiotic-functionalized 
AuNPs became too hydrophobic, but at low concentrations 
there was insufficient binding of the AuNPs to the test line of 
the LFA. Using QCM-D data, it was calculated that in saturated 
surfaces functionalized with BSA-cephalexin, there are 6050 
cephalexin molecules bound per 20 nm AuNP (Supporting 
information, Table S3). Stability tests found that the optimized 
cephalexin-BSA-AuNPs were stable in up to 100% urine 
(Supporting Information, Fig. S4 and Table S2).
Antibiotic-functionalized AuNPs Binding Experiments
QCM-D was used to ascertain whether cephalexin molecules 
bound to a surface via a BSA layer were able to bind to PBP3 and 
whether -lactamases could access and hydrolyze the 
immobilized cephalexin. For clarity, only the frequency data of 
key steps in the QCM-D experiments are discussed herein, with 
the full experimental data, including dissipation data, provided 
in the Supporting Information. 
Previously, we demonstrated that cephalexin attached to a thiol 
surface via a polyethylene glycol (PEG) linker or a short alkane 
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tether were able to react with PBP3 and -lactamases.16 To 
investigate the BSA-cephalexin surface chemistry developed for 
AuNPs functionalization (Fig. 1 (b) (i)), Au-coated QCMD sensors 
were first functionalized with BSA followed by attachment of   
cephalexin using the NHS ester analogue (Fig. 3). The drug-
covered surface was subsequently challenged with a solution of 
PBP3 followed by a washing step (Fig. 4). The average 
magnitude of the resulting frequency shift (−23 Hz) suggested 
that approximately 8.3 × 1012 PBPs/cm2 were bound to the 
β-lactam antibiotics on the surface (S3 and S4). This surface 
density is 83% of the density previously reported for a 
monolayer of PBP3 (1 × 1013 proteins/cm2).12 We also note, the 
PBPs remained bound to the surface following washing with 2% 
(a)
(b)
Fig. 4: (a) QCM-D experiment of PBP3 binding to a BSA-
cephalexin surface; (b) The number of PBPs bound after the 
final wash for +/- -lactamase. Data reported as mean value 
with ± standard deviation error bars.
sodium dodecyl sulfate (SDS) confirming that the antibiotics 
immobilized using this surface chemistry were able to 
covalently bind with the PBPs. In a parallel experiment, two of 
the cephalexin-functionalized sensors were pre-exposed to a 
solution containing a blend of -lactamases before introducing 
the PBP3 solution (S1 and S2). In order for the LFA to detect 
active -lactamases, the enzymes must be able to hydrolyze the 
surface-bound antibiotics, thereby preventing binding between 
cephalexin and PBP. As shown in Fig. 4, the amount of PBPs 
binding was reduced by 60% following exposure of the 
cephalexin surface to -lactamase, thus demonstrating that a 
significant number of the BSA-bound antibiotics were 
(a) 
 (b)
Fig. 5: (a) Immobilization steps used in QCM-D experiment to 
replicate the LFA conditions: (i) NiSO4, (ii) PBP3 immobilization 
(iii) Antibiotic-functionalized AuNPs - only binding if antibiotics 
are intact; (b) QCM-D experiment with immobilized PBP3: S1/S2 
confirmed binding of intact antibiotic-functionalized AuNPs; 
S3/S4 show no binding to PBP3 when the antibiotic-























S1 - beta-lactamase exposed
S2 - beta-lactamase exposed
S3 - buffer control














































S3 - Cephalexin-AuNPs pre-exposed to beta-lactamases
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hydrolyzed and therefore unable to bind the PBPs.
Having demonstrated the immobilization chemistry on planar 
surfaces, further QCMD experiments were performed to 
investigate cephalexin-PBP interactions using the antibiotic-
functionalized AuNPs. In order to immobilize the PBP3 onto the 
sensor surface a His-tag strategy was used as shown in Fig. 5 (a): 
SiO2 sensors were first functionalized with MPTES to provide a 
thiol handle for the attachment of a Ni2+ binding motif using 
maleimide conjugation. The functionalized sensors were then 
loaded into the QCM-D flow modules and a NiSO4 solution was 
used to load the surface with Ni2+ followed by a buffer washing 
step to remove excess reagents (Supporting Information Fig. 
S6). The sensor surfaces were then exposed to a solution of 
PBP3 with an N-terminal deca-His-tag followed by another 
washing step to remove non-specifically bound proteins. Once 
functionalized with PBP3, the surfaces were challenged with 
one of two samples: (i) antibiotic-functionalized AuNPs and (ii) 
antibiotic-functionalized AuNPs in which the cephalexin was 
hydrolyzed by pre-exposure to a solution of -lactamases. As 
shown in Fig. 5 (b), we observed significant binding between the 
antibiotic-functionalized AuNPs and the surface immobilized 
PBP3 (S1 and S2), whereas the AuNPs that were pre-incubated 
with -lactamases did not bind to the PBP3 surface (S3 and S4). 
These experiments confirm that the cephalexin-AuNPs can be 
used to probe for/detect -lactamase activity, with formation 
of the PBP-cephalexin-AuNPs complex indicating the absence of 
-lactamase activity.  
LFA Optimization
A total of 15 membrane types were trialed for use in the LFA, 
and HF090MC100 was identified as the optimal membrane. See 
the Supporting Information (Table S4) for the full list of the 
membranes investigated.
Test strips were prepared containing PBP3 as the test spot. 
Initial tests employed two different species of AuNP. The first 
were AuNPs functionalized with BSA, designed to test the 
selectivity of the test spot and assess non-specific binding. The 
second were AuNPs functionalized with BSA-cephalexin, which 
would bind to the PBP3 of the test spot provided the cephalexin 
molecules were active. Preliminary tests revealed issues with 
non-specific binding to the test spot, which was rectified by the 
optimization of the running buffer to PBS with 1 mM EDTA and 
1% v/v Triton™ X-100. All subsequent experiments employed 
this optimized buffer. It was successfully shown that the 
cephalexin-AuNPs were selective for PBP3 and with no 
detectable background signal due to non-specific binding, Fig. 6 
(a). Furthermore, after exposing the cephalexin-AuNPs to a 
blend of recombinant -lactamases for 5 h, the AuNPs were no 
longer able to bind to the test spot (Fig. 6 (b)). This 
demonstrates the principle of using the cephalexin-AuNPs in an 
LFA to detect -lactamase activity; with a visible red spot at the 
PBP test region indicating no -lactamases present or lack of -
lactamase activity, whereas the absence of a spot would 
indicate that active -lactamases are present (Fig. 6 (b)). 
The concentration of PBP3 within the test spot was then 
optimized to ensure sufficient binding of AuNPs for a clearly 
Fig. 6: LFA test results, red color due to AuNPs present: (a) 
Specificity of (i) cephalexin-AuNPs vs (ii) BSA-AuNPs; (b) proof 
of concept in detecting -lactamases activity using antibiotic-
functionalized AuNPs: (iii) preincubated with -lactamases and 
(iv) no -lactamases; (c) compatibility of antibiotic- 
functionalized AuNPs with a streptavidin/biotin control: (v)  
antibiotic-functionalized AuNPs only vs (vi) antibiotic-
functionalized AuNPs mixed with streptavidin-AuNPs; (d) -
lactamase tests using a mixture of antibiotic-functionalized 
AuNPs and streptavidin-AuNPs: (vii) mixed AuNPs, no -
lactamases and (viii) mixed AuNPs, preincubated with -
lactamases.
visible colored spot appearing in the test region. It was also 
critical to maintain the flow of the AuNPs through the 
membrane that could otherwise produce false readings. An 
initial screen of 2 L spots at 10 M, 1 M, 100 nM, 10 nM, and 
1 nM of PBP3 in PBS found that 1 M was optimal (Supporting 
information Fig. S7). A second screen over the narrower range 
of 2 M - 125 nM, identified that non-specific binding was 
occurring at the higher concentrations; ultimately, 750 nM was 
identified as the optimal concentration. During initial trials, it 
was noted that the test spot appeared in a ring shape with a 
clear region in the center (e.g. Fig. 6 (i)), indicating that the 
protein was not evenly immobilized onto the membrane during 
the preparation of the test strips. This was remedied by 
increasing the NaCl concentration of the PBP3 solution used 
when spotting the protein onto the membrane (from 137 mM 
to 320 mM).
Optimized LFAs were prepared and used to optimize the 
concentration of cephalexin-NHS used in the preparation of the 
antibiotic-functionalized AuNPs. By testing across a 
concentration gradient, it was determined that a final 
Test
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cephalexin-NHS:AuNP ratio of 130,000:1 was optimal. Due to 
the unstable nature of NHS esters under aqueous conditions, a 
large proportion of the tethered antibiotics are likely to be 
hydrolyzed in the PBS buffer before reacting with the BSA lysine 
residues. To minimize this loss, a stock solution of cephalexin-
NHS in DMSO at 1 mg/100L was used, with the addition of the 
required volume to the PBS solution of BSA-AuNP to give the 
required ratio.
Limit of Detection in vitro
The sensitivity of the LFA was investigated using five selected 
recombinant -lactamases in buffer. The β-lactamase family of 
enzymes is vast, with over 2500 unique proteins identified.20 β-
lactamases can be categorized into subsets (class A, B, C, or D), 
based on their protein sequence. TEM-1 was included as this 
class A β-lactamase is one of the most common β-lactamases 
found in Gram-negative bacteria.21 AmpC is a class C β-
lactamase known to confer resistance to cephalosporins 
including cephalexin, the antibiotic used in the preparation of 
the antibiotic-functionalized AuNPs.20 CTX-M-1 and CTX-M-15 
are ESBLs from class A; these plasmid-encoded enzymes22 are 
associated with multi-drug resistant infections.23,24  The class B 
metallo-β-lactamase NDM-1 was also included, known to 
hydrolyze penicillins, cephalosporins, and even last resort 
carbapenems by a mechanism catalyzed by one or two zinc ions 
present in the active site.25 
Each of the five selected -lactamases was tested across a range 
of concentrations, in x10 incremental dilutions. The antibiotic-
functionalized AuNPs were incubated in these prepared 
solutions for 1 h at 37 °C before being added to the LFA strips. 
A screen of three different temperatures (20 °C, 37 °C, and 50 
°C) identified 37 °C to be the optimal temperature for the 
incubation step (Supporting Information, Table S5). Details on 
the concentrations screened are provided in the Supporting 
Information (Tables S6(a) and S6(b)). Ideally, for point-of-care 
applications the diagnostics should be rapid, thus the detection 
limit after 1 h incubation with -lactamases was investigated. 
The test results and limits of detection (LOD) for each of the 
selected -lactamases are shown in Table 1. 
Further testing was also performed in urine spiked with -
lactamases (Table 1) to investigate the effects of running the 
diagnostic in a complex media. The LOD was 10-fold less 
sensitive for the detection of CTX-M-1 and NDM-1 in urine; 
however, for the three other -lactamases trialed, the LOD in 
urine was comparable with the results obtained using buffer. 
These results demonstrated that the design of the antibiotic-
functionalized AuNPs and membrane-blocking protocol were 
successful in minimizing biofouling. Further control tests 
confirmed that 2% boric acid, a preservative commonly added 
to urine samples in a clinical setting, did not affect the LFA. The 
LFA is also compatible with up to 2.5% v/v blood in urine, 
suggesting that the antibiotic-functionalized AuNPs would be 
suitable for detecting in infections presenting with hematuria 
(Supporting Information, Table S7). 
Previous studies have reported that the periplasmic 
concentrations of -lactamases can range from 3.7 M - 1 mM
-lactamase Buffer LOD Urine LOD
TEM-1 6 M 6 M
AmpC 12 M 12 M
CTX-M-1 780 nM 7.8 M
CTX-M-15 60 nM 60 nM
NDM-1 11 nM 110 nM
Table 1. LOD of -lactamases in buffer and in urine, after 1 h 
incubation.
in an E. coli cell.26-28 E. coli is the most common pathogen in 
UTIs, with a urine sample typically containing between 104 – 106 
CFU/mL. Using these reported values, it is expected that the 
-lactamase concentration in a UTI urine sample will range 
between 2.4 fM – 66 pM (assuming the -lactamases are fully 
lysed from mature bacterial cells with a periplasmic volume of 
20% of the total cell volume). To confirm this predicted range, 
the -lactamase concentration of cell lysates was determined 
for two strains of E. coli, expressing different -lactamases, 
using the nitrocefin assay.29 This colorimetric assay is not 
sufficiently sensitive to detect -lactamases at the relevant 
concentrations; however, through linear regression of the 
correlation of CFU/mL to -lactamase concentration 
(Supporting Information, Fig. S11 and S12), the -lactamase 
concentrations of UTI samples with 104-106 CFU/mL of the two 
selected strains were found to fall within the predicted 
concentration range of -lactamases (Supporting Information, 
Table S8). These results identified that enzyme pre-
concentration or bacterial culturing would be necessary for the 
direct detection of active -lactamases in a UTI sample. This was 
confirmed through tests carried out using the LFA with 
simulated UTI urine samples at 106 CFU/mL of CTX-M-15 
producing E. coli (data not shown). We note, the antibiotic-
functionalized AuNPs were found to be compatible in 
microbiologically-important systems such as LB and lysis buffers 
(specifically, BugBuster® as well as PBS with 500 mM sucrose 
and 1 mM EDTA, pH 7.4, for periplasmic extractions) allowing 
the LFA to also be used following bacterial culturing.
The LFA described herein provides proof of concept towards the 
development of a point-of-care test for active -lactamases in a 
patient’s sample. To reach the required sensitivity for direct 
testing for the enzyme activity in urine samples, alternative 
antibiotic-functionalized nanoparticles (NPs) could be 
implemented in this LFA platform. In nanodiagnostics, AuNPs 
used in a colorimetric readout (as in the LFA detailed here) is a 
common choice; however, this method is reported to have low 
sensitivity, typically within the M-pM range.30 By using 
alternative NPs the sensitivity could be significantly improved, 
such as fluorescent NPs (nM-fM range) or magnetic NPs (pM-
aM range). Another approach would be to adapt the LFA using 
AuNPs to have a more sensitive readout method, as the optical 
color change read by eye is limited by a higher concentration of 
AuNPs required to produce the visible red line. For example, it 
has been shown that using photon counting to quantify the 
AuNPs binding in an LFA can greatly improve the LOD.31 For a 
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recent review on approaches to improving the sensitivity of 
LFAs, see the perspective by Bishop et al. 32 
Summary and Conclusion
Antibiotic-functionalized AuNPs have been successfully 
developed for the detection of -lactamases in complex media. 
Using a surface chemistry strategy that includes a foundation 
layer of BSA on the AuNPs, produced hydrophilic AuNPs that 
were resistant to biofouling and allowed for application of these 
detection tools in biological samples such as urine, LB, and 
periplasmic extractions. QCM-D studies confirmed that these 
antibiotic-functionalized AuNPs were recognized by -
lactamases, resulting in the hydrolysis of  surface-bound 
antibiotics. It was also shown that the binding of these 
antibiotic-functionalized AuNPs to PBP3 can be used to indicate 
that the antibiotics were intact, thus monitoring for the binding 
interaction can infer the presence or absence of -lactamases. 
The antibiotic-functionalized AuNPs were successfully applied 
to an LFA platform as a simple test for the presence of active -
lactamases. The LFA was shown to detect one of the 
investigated -lactamases (NDM-1) down to a concentration of 
11 nM. With estimated -lactamase concentrations in UTI urine 
samples ranging from fM to pM, pre-concentration steps would 
have to precede sample application to enable detection. 
Notably, it was found that the test is more sensitive to the 
enzymes found in difficult-to-treat infections (CTX-M-15 and 
NDM-1) over the more standard -lactamases (TEM-1 and 
AmpC). Investigations using undiluted urine spiked with -
lactamases demonstrated the compatibility of the antibiotic-
functionalized AuNPs in detecting -lactamase activity in 
complex media. The LFA described herein allows for the 
detection of -lactamase activity, thus providing an alternative 
method of detecting these enzymes, that is complementary to 
antibody-based testing.
This work provides proof of concept that these antibiotic-
functionalized AuNPs can be used to develop biosensors for one 
of the major contributors towards AMR. By using AuNPs, there 
is a plethora of technologies in which these novel tools of 
detection are compatible, which could lead to the development 
of vital point-of-care diagnostics for bacterial infections.
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